<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209000</url>
  </required_header>
  <id_info>
    <org_study_id>6801</org_study_id>
    <secondary_id>1U54DK083912</secondary_id>
    <nct_id>NCT01209000</nct_id>
    <nct_alias>NCT01240564</nct_alias>
  </id_info>
  <brief_title>Nephrotic Syndrome Study Network</brief_title>
  <acronym>NEPTUNE</acronym>
  <official_title>Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The NephCure Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous
      nephropathy (MN), generate an enormous individual and societal financial burden, accounting
      for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual
      cost in the US of more than $3 billion. However, the clinical classification of these
      diseases is widely believed to be inadequate by the scientific community. Given the poor
      understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies
      are imperfect. The therapies lack a clear biological basis, and as many families have
      experienced, they are often not beneficial, and in fact may be significantly toxic. Given
      these observations, it is essential that research be conducted that address these serious
      obstacles to effectively caring for patients.

      In response to a request for applications by the National Institutes of Health, Office of
      Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a
      number of affiliated universities joined together with The NephCure Foundation the NIDDK, the
      ORDR, and the University of Michigan in collaboration towards the establishment of a
      Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.

      Through this consortium the investigators hope to understand the fundamental biology of these
      rare diseases and aim to bank long-term observational data and corresponding biological
      specimens for researchers to access and further enrich.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately
      12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children.
      Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change
      Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose
      prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate
      mofetil and other immunosuppressive agents, which all carry significant side effects. Failure
      to obtain remission using the current treatment approaches frequently results in progression
      to ESRD with its associated costs, morbidities, and mortality. In the North American
      Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric
      patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within
      two years of being enrolled in the disease registry. FSGS also has a high recurrence rate
      following kidney transplantation (30-40%) and is the most common recurrent disease leading to
      allograft loss.

      The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and
      MN, if in the absence of other underlying causes, glomerular histology shows a specific
      histological pattern. This classification does not adequately predict the heterogeneous
      natural history of patients with FSGS, MCD, and MN. Major advances in understanding the
      pathogenesis of FSGS and MCD have come over the last ten years from the identification of
      several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS)
      presenting with FSGS or MCD histopathology in humans and model organisms. These functionally
      distinct genetic disorders can present with indistinguishable FSGS lesions on histology
      confirming the presence of heterogeneous pathogenic mechanisms under the current histological
      diagnoses.

      The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a
      descriptive classification system in which heterogeneous disorders are grouped together. This
      invariably consigns these heterogeneous patients to the same therapeutic approaches, which
      use blunt immunosuppressive drugs that lack a clear biological basis, are often not
      beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a
      strong case that concerted and innovative investigational strategies combining basic science,
      translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for
      these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical
      and translational research in patients with FSGS/MCD and MN.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event rate of change in urinary protein excretion and renal function.</measure>
    <time_frame>60 months</time_frame>
    <description>Defined as remission, partial remission and non-remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change in renal function.</measure>
    <time_frame>60 months</time_frame>
    <description>Defined as:
25 mls/min/1.73m2 reduction in follow-up estimated GFR (using the 4-variable MDRD equation for ages ≥18 years and modified Schwartz for ages &lt;18 years) compared to baseline estimated GFR
50% decline in follow-up estimated GFR compared to baseline measurement
End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or preemptive kidney transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life:</measure>
    <time_frame>60 months</time_frame>
    <description>Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancies</measure>
    <time_frame>60 months</time_frame>
    <description>Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections, Serious and Systemic</measure>
    <time_frame>60 months</time_frame>
    <description>Infections including one of the following:
Documented diagnosis of infection of the skin or subcutaneous tissue (e.g. cellulitis), vascular system, peritoneum, or any vital organ requiring the use of parenteral antibiotics and/or oral antibiotics alone or in combination for a treatment interval of ≥72 hours.
Hospitalization for treatment of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events</measure>
    <time_frame>60 months</time_frame>
    <description>Documented diagnosis of one of the following:
Embolic cerebrovascular accident
Deep venous thrombosis
Renal vein thrombosis or
Pulmonary embolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>60 months</time_frame>
    <description>Documented hospital admission, including observation for ≥24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Department/ Observation Unit Visit</measure>
    <time_frame>60 months</time_frame>
    <description>Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>60 months</time_frame>
    <description>Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy &lt;3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>60 months</time_frame>
    <description>Documentation of death that is secondary to infection or sepsis.
Cardiovascular/Cerebrovascular-related Death: Sudden death; Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event
Documentation of death secondary to cancer
Other Death: Documentation of death that does not fall into the above categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset Diabetes</measure>
    <time_frame>60 months</time_frame>
    <description>Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:
Documented diagnosis of diabetes in medical record
Casual (non-fasting) blood glucose &gt; 200 mg/dL c) Fasting blood glucose &gt; 126 mg/dL d) 2 hour glucose &gt; 200 after oral glucose tolerance test e) chronic use (&gt;6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C &gt;= 6.5%</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Minimal Change Disease (MCD)</condition>
  <condition>Membranous Nephropathy</condition>
  <condition>Glomerulosclerosis, Focal Segmental</condition>
  <arm_group>
    <arm_group_label>FSGS/MCD Cohort (Cohort A)</arm_group_label>
    <description>Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort
Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.
Eligible participants must be scheduled for a clinically indicated renal biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN Cohort (Cohort A)</arm_group_label>
    <description>Membranous Nephropathy (MN) Cohort
Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.
Eligible participants must be scheduled for a clinically indicated renal biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other glomerulopathies cohort</arm_group_label>
    <description>Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.
Eligible participants must be scheduled for a clinically indicated renal biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cNEPTUNE (Cohort B)</arm_group_label>
    <description>Participants &lt; 19 years of age, with &lt; 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney Biopsy</intervention_name>
    <description>Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.</description>
    <arm_group_label>FSGS/MCD Cohort (Cohort A)</arm_group_label>
    <arm_group_label>MN Cohort (Cohort A)</arm_group_label>
    <arm_group_label>Other glomerulopathies cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Renal tissue core (from clinically indicated kidney biopsy procedure) Blood products Urine
      products DNA/RNA specimens (declining consent does not forego participant eligibility)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or
        proteinuric renal disease or pediatric participants not previously biopsied, who present
        for patient care at participating clinical centers will be eligible for Cohort A (biopsy
        cohort) study population targeted for enrollment into the NEPTUNE study.

        To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B,
        a non-biopsy cohort has been initiated for Protocol V4.0. This population, &lt;19 years of
        age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy
        exposure, will also be targeted for enrollment into the cNEPTUNE study.

        Potential participants willing to receive their initial care and subsequent follow-up study
        visits at one of these sites are welcome to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cohort A (biopsy cohort) Inclusion Criteria:

        Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric
        participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting
        the following inclusion criteria:

          -  Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine
             ratio equivalent at the time of diagnosis or within 3 months of the
             screening/eligibility visit.

          -  Scheduled renal biopsy

        Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:

          -  Age &lt;19 years of age

          -  Initial presentation with &lt;30 days immunosuppression therapy

          -  Proteinuria/nephrotic

               -  UA&gt;2+ and edema OR

               -  UA&gt;2+ and serum albumin &lt;3 OR

               -  UPC &gt; 2g/g and serum albumin &lt;3

        Exclusion Criteria (Cohort A&amp;B):

          -  Prior solid organ transplant

          -  A clinical diagnosis of glomerulopathy without diagnostic renal biopsy

          -  Clinical, serological or histological evidence of systemic lupus erythematosus (SLE)
             as defined by the ARA criteria. Patients with membranous in combination with SLE will
             be excluded because this entity is well defined within the International Society of
             Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently
             overlaps with other classification categories of SLE nephritis (68)

          -  Clinical or histological evidence of other renal diseases (Alport, Nail Patella,
             Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas),
             genito-urinary malformations with vesico-urethral reflux or renal dysplasia)

          -  Known systemic disease diagnosis at time of enrollment with a life expectancy less
             than 6 months

          -  Unwillingness or inability to give a comprehensive informed consent

          -  Unwillingness to comply with study procedures and visit schedule

          -  Institutionalized individuals (e.g., prisoners)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Kretzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrysta C. Lienczewski, BS</last_name>
    <phone>1-877-9-NEPTUNE</phone>
    <email>NEPTUNE-Study@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tina Mainieri, MS</last_name>
    <phone>1-877-9-NEPTUNE</phone>
    <email>NEPTUNE-Study@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California-Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Whitted, BS</last_name>
      <phone>323-361-7299</phone>
      <email>lwhitted@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Lemley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kshama Mehta, PhD</last_name>
      <phone>650-736-1822</phone>
      <email>krmehta@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Lafayette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine LaPage</last_name>
      <phone>310-222-4104</phone>
      <email>jlapage@labiomed.org</email>
    </contact>
    <investigator>
      <last_name>Sharon Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bidot</last_name>
      <phone>305-243-8973</phone>
      <email>cbidot2@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Alessia Fornoni, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University and Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Lee</last_name>
      <phone>404-712-9998</phone>
      <email>brian.lee3@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Laurence Greenbaum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Stroger Cook County Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Itteera</last_name>
      <phone>312-864-4614</phone>
      <email>mitteera@cookcountyhhs.org</email>
    </contact>
    <investigator>
      <last_name>Ambarish Athavale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Boynton</last_name>
      <phone>443-287-9051</phone>
      <email>sboynto3@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Alicia Neu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Choi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney Disease Section, NIDDK, NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Castro-Rubio</last_name>
      <phone>301-451-6994</phone>
      <email>castrorubioem@niddk.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Jeffrey P. Kopp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Mott Children's Hospital, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Herreshoff</last_name>
      <phone>734-232-4851</phone>
      <email>egalopin@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Debbie Gipson, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrysta C. Lienczewski, BS - adult</last_name>
      <phone>734-615-5021</phone>
      <email>boridley@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Pitter, BS - peds</last_name>
      <phone>734-936-4644</phone>
      <email>raltrine@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Kretzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Chernitskiy, CCRC</last_name>
      <phone>507-255-0231</phone>
      <email>Chernitskiy.Vladimir@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Fernando Fervenza, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Lieske, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie C. Hogan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Haney, RN</last_name>
      <phone>816-234-3891</phone>
      <email>cjhaney@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Tarak Srivastava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalli Gramma, RN</last_name>
      <phone>718-470-3499</phone>
      <email>kgramma1@binghamton.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Sethna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Modersitzki, MPH - adult</last_name>
      <phone>212-686-7500</phone>
      <phone_ext>6379</phone_ext>
      <email>Frank.Modersitzki@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Vento, RN - peds</last_name>
      <email>svento@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Olga Zhadnova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Trachtman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Modersitzki, MPH</last_name>
      <phone>212-686-7500</phone>
      <phone_ext>6379</phone_ext>
      <email>Frank.Modersitzki@va.gov</email>
    </contact>
    <investigator>
      <last_name>Laura Barisoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Zhadnova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Veterans Administration</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Modersitzki, MPH</last_name>
      <phone>212-686-7500</phone>
      <phone_ext>6379</phone_ext>
      <email>Frank.Modersitzki@va.gov</email>
    </contact>
    <investigator>
      <last_name>Laura Barisoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Zhadnova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Toledo, RN</last_name>
      <phone>212-305-6842</phone>
      <email>mt3013@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Bomback, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Flynn, RN</last_name>
      <phone>718-655-1120</phone>
      <email>pflynn@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Frederick Kaskel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Woroniecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Froment</last_name>
      <phone>919-923-1382</phone>
      <email>Anne_Froment@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Grubbs, CPNP</last_name>
      <phone>919-966-2561</phone>
      <phone_ext>245</phone_ext>
      <email>sandra_grubbs@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick H. Nachman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan L. Hogan, PhD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keisha Gibson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitzie Spainhour</last_name>
      <phone>336-716-4246</phone>
      <email>mhspain@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Gray</last_name>
      <email>stefgray@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jen-Jar Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Schachere, RN</last_name>
      <phone>216-778-4321</phone>
      <email>mrs27@case.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Dell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Hospital at Case Western Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Schachere, RN</last_name>
      <phone>216-778-4321</phone>
      <email>mrs27@case.edu</email>
    </contact>
    <investigator>
      <last_name>John Sedor, MI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Bellar, RN</last_name>
      <email>bellara@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Meghan Villarreal, RN</last_name>
      <email>villarm@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Dell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Kallem, MS</last_name>
      <phone>484-358-0315</phone>
      <email>krishna.kallem@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Meyers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Kallem, MD - adult, MS</last_name>
      <phone>484-358-0315</phone>
      <email>krishna.kallem@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Cerecino, BS - peds</last_name>
      <email>CerecinoF@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Holzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Pfeffer, BS</last_name>
      <phone>215-707-4712</phone>
      <email>zoe.pfeffer@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Crystal Gadegbeku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iris Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Johnson, LVN</last_name>
      <phone>214-645-8263</phone>
      <email>natalie.johnson@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kamal Sambandam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kelton</last_name>
      <phone>206-884-1372</phone>
      <email>megan.kelton@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sangeeta Hingorani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Klepach</last_name>
      <phone>203-221-3938</phone>
      <email>kkhome@nephrology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Peter J. Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Cooper, CCRC</last_name>
      <phone>509-474-4327</phone>
      <email>Ann.Cooper@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Franks, BSN, CCRC</last_name>
      <phone>509-474-4320</phone>
      <email>Ruth.Franks@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Tuttle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Central Hospital</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 4Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tami Baker</last_name>
      <phone>905-508-5911</phone>
      <phone_ext>402</phone_ext>
      <email>yorknephrology1@rogers.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Chen</last_name>
      <phone>905-508-5911</phone>
      <email>yorknephrology1@rogers.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Pandes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scarborough Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dione Rochester, BSc</last_name>
      <phone>416-279-0855</phone>
      <phone_ext>230</phone_ext>
      <email>nephro_associates@yahoo.ca</email>
    </contact>
    <investigator>
      <last_name>Paul YW Tam, FRCP, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ling, MD</last_name>
      <phone>416-340-3514</phone>
      <email>pling@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Phillip Boll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ling, MD</last_name>
      <phone>416-340-3514</phone>
      <email>pling@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle Hladunewich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ling, MD</last_name>
      <phone>416-340-3514</phone>
      <email>pling@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Martin Romano, MD</last_name>
      <email>Martin.Romano@trilliumhealthpartners.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Cattran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Reich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Hladunewich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/NEPTUNE/</url>
    <description>Rare Diseases NEPTUNE Homepage</description>
  </link>
  <link>
    <url>http://www.nephcure.org</url>
    <description>Patient Advocacy group for FSGS/MCD</description>
  </link>
  <link>
    <url>http://www.halpinfoundation.org/</url>
    <description>Patient advocacy group for MN</description>
  </link>
  <link>
    <url>http://www.neptune-study.org</url>
    <description>The NEPTUNE Study Homepage</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Matthias Kretzler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Focal and Segmental Glomerulosclerosis</keyword>
  <keyword>Focal &amp; Segmental Glomerulosclerosis</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <keyword>Minimal change disease</keyword>
  <keyword>MCD</keyword>
  <keyword>Membranous Nephropathy</keyword>
  <keyword>MN</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Neph Syndrome</keyword>
  <keyword>NEPTUNE</keyword>
  <keyword>NephCure</keyword>
  <keyword>Halpin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

